These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 15815726

  • 1. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 2. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [Abstract] [Full Text] [Related]

  • 3. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q, Nishiuchi R, Kitamura T, Kersey JH.
    Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
    [Abstract] [Full Text] [Related]

  • 4. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 5. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
    Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.
    J Biol Chem; 2003 Aug 29; 278(35):32892-8. PubMed ID: 12815052
    [Abstract] [Full Text] [Related]

  • 6. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun 29; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D.
    Leukemia; 2002 Oct 29; 16(10):2027-36. PubMed ID: 12357354
    [Abstract] [Full Text] [Related]

  • 8. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X, Liu L, Sternberg D, Tang L, Galinsky I, DeAngelo D, Stone R.
    Cancer Res; 2005 Aug 15; 65(16):7338-47. PubMed ID: 16103085
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H.
    Blood; 2000 Dec 01; 96(12):3907-14. PubMed ID: 11090077
    [Abstract] [Full Text] [Related]

  • 11. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, Hiddemann W, Spiekermann K.
    Blood; 2004 Mar 15; 103(6):2266-75. PubMed ID: 14604974
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J.
    Blood; 2003 Jul 15; 102(2):646-51. PubMed ID: 12663439
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT, Levis M, Small D.
    Br J Haematol; 2006 Sep 15; 134(5):500-9. PubMed ID: 16869825
    [Abstract] [Full Text] [Related]

  • 18. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.
    Blood; 2003 May 01; 101(9):3597-605. PubMed ID: 12531805
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
    Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM.
    Leukemia; 2007 Mar 01; 21(3):439-45. PubMed ID: 17205056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.